Opus Genetics Launches Gene Therapy Trial for Blindness
Opus Genetics will launch a clinical trial of OPGx-MERTK, an adeno-associated virus gene therapy for MERTK-related retinitis pigmentosa, in...
Opus Genetics will launch a clinical trial of OPGx-MERTK, an adeno-associated virus gene therapy for MERTK-related retinitis pigmentosa, in...
The University of Virginia has opened a first-in-human program for hCitH3-mAb, a monoclonal antibody intended to neutralize citrullinated histone...
The initiative will enroll up to 40 adults with PTSD for 12 weeks of adjunctive treatment with gammaCore Sapphire,...
Aligos has enrolled 144 patients into its Phase 2 B-SUPREME study of pevifoscorvir sodium (ALG-000184) in chronic hepatitis B,...
Exicure’s open-label, multicenter Phase 2 trial in multiple myeloma reported that 89.7% of patients met the study’s primary mobilization...
In a first-in-human pilot of 10 preoperatively potent men undergoing nerve‑sparing robotic radical prostatectomy, Comphya’s implantable cavernous nerve neurostimulator...
Daridorexant 50 mg met the primary endpoint of change from baseline in subjective total sleep time at Day 28...
In preclinical Lyme disease models, subtle alterations to the Borrelia burgdorferi peptidoglycan nearly eliminated arthritis despite ongoing infection at...
In preclinical models of diabetic macular edema, oral BGE-102 nearly eliminated retinal vascular leakage and preserved up to 90%...
In an open-label study of 10 patients with non-active secondary progressive multiple sclerosis, intranasal foralumab showed no serious or...